For example, BO‐110 and other dsRNA‐based polyplexes are being actively pursued for their ability to (re)activate the innate immune system in aggressive cancers, with a particular interest in cytotoxic CD8+ T cells, among others (Akira & Takeda, 2004; Hervas‐Stubbs et al, 2011; Aznar et al, 2019). Here, CD8A is linked to cancer.